Last $94.38 USD
Change Today +0.20 / 0.21%
Volume 819.7K
NVS On Other Exchanges
Symbol
Exchange
SIX Swiss Ex
Xetra
New York
OTC US
Mexico
Frankfurt
SIX Swiss Ex
As of 8:04 PM 09/16/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Lichtstrasse 35

Basel, 4056

Switzerland

Phone: 41 61 324 11 11

Fax:

l); and Azacitidine for injection (Celgene's Vidaza). Sandoz received its first European approvals in Denmark in December 2013 and in other countries, including Germany and Sweden in January 2014 for its AirFluSal Forspiro respiratory inhaler for asthma and chronic obstructive pulmonary disease patients, which offers the proven combination of salmeterol (a long-acting inhaled beta2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative new inhalation device. The product's safety, efficacy and equivalence have been proven in multiple clinical trials. Key Marketed Products Retail Generics: The company offers Amoxicillin/clavulanic acid; Enoxaparin sodium injection; Acetylcysteine; Fentanyl; Omeprazole; Linex (lactobacillus); Tacrolimus; Sumatriptan; Atorvastatin; and Diclofenac. Anti-Infectives: The company offers Oral and sterile penicillins; Oral and sterile cephalosporins; Clavulanic acid and mixtures with clavulanic acid; and Classical and semisynthetic erythromycins. Intermediates: The company offers various cephalosporin intermediates; Erythromycin base; and various crude compounds produced by fermentation. Biopharmaceuticals: The company offers Omnitrope; Binocrit and Epoetin alfa Hexal; and Zarzio and Filgrastim Hexal. Oncology Injectables: The company offers Leuprorelin; Docetaxel; Methotrexate; Azacitidine; Paclitaxel; Gemcitabine; Etoposide; Oxaliplatin; Irinotecan; and Doxorubicin. Principal Markets The U.S. and Europe are the principal markets for Sandoz, although Sandoz sells products in approximately 140 countries. Marketing and Sales Sandoz sells a portfolio of generic pharmaceutical products to wholesalers, pharmacies, hospitals, and other healthcare outlets. The company’s Anti-Infectives business supplies Retail Generics and the pharmaceutical industry worldwide with active pharmaceutical ingredients and intermediates, primarily in the field of antibiotics VACCINES AND DIAGNOSTICS This division researches, develops, manufactures, distributes, and sells preventive human vaccines and novel blood-screening diagnostic tools, which help protect the world's blood supply by preventing the spread of infectious diseases. Novartis Vaccines' products include meningococcal, influenza, pediatric, adult, and travel vaccines. Novartis Diagnostics is dedicated to increasing transfusion safety with NAT blood testing products and immunoassay reagents that detect infectious disease worldwide and through distribution of research use blood genotyping products in select markets. The product portfolio of this division includes approximately 15 marketed products. In addition, this division's portfolio of development projects includes approximately 15 new products in various stages of clinical development. In January 2013, Bexsero, the Novartis Meningococcal Group B Vaccine (rDNA, component, adsorbed) received EU approval, following a positive opinion from the CHMP in November 2012. Global incidence of invasive meningococcal Group B disease (MenB) is estimated to be between 20,000 and 80,000 cases per year, with an approximate 10% fatality rate. The company is working with health authorities to provide access to Bexsero as soon as possible. In 2013, the UK Joint Commission on Vaccination and Immunisation (JCVI) released its interim recommendation regarding Bexsero. Principal Markets The principal markets for the company’s Vaccines and Diagnostics division include the U.S. and Europe. Marketing and Sales The company’s primary Vaccines marketing and sales organizations are based in Switzerland, Germany, the U.K., Italy, and the U.S. It intends to expand its operations in China, India, Europe, and Latin America. In the U.S., the company markets influenza, meningococcal, Japanese Encephalitis, and rabies vaccines through a network of wholesalers and distributors, as well as direct to primary customers. Direct sales efforts are focused on public health and distributor channels, and on non-traditional channels, such as employers, chain drug headquarters, and service providers. Research and Development In 2013, the Vaccines and Diagnostics Division expens

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVS:US $94.38 USD +0.20

NVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Merck & Co Inc $59.99 USD +0.47
Pfizer Inc $30.05 USD +0.13
Roche Holding AG SFr.278.30 CHF +0.80
Sanofi €87.12 EUR +0.62
Procter & Gamble Co/The $84.08 USD +0.21
View Industry Companies
 

Industry Analysis

NVS

Industry Average

Valuation NVS Industry Range
Price/Earnings 25.3x
Price/Sales 3.9x
Price/Book 3.2x
Price/Cash Flow 26.1x
TEV/Sales 3.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-ADR, please visit www.novartis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.